Evidence map›Paper›PMID 28361894›Full record

ArticleScientific reports2017

The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption.

Manon F Pritchard, Lydia C Powell, Saira Khan, Peter C Griffiths, Omar T Mansour, Ralf Schweins, Konrad Beck, Niklaas J Buurma, Christopher E Dempsey, Chris J Wright and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Manon F PritchardAdvanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Heath Park, Cardiff, UK.
Lydia C PowellAdvanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Heath Park, Cardiff, UK.
Saira KhanAdvanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Heath Park, Cardiff, UK.
Peter C GriffithsDepartment of Pharmaceutical, Chemical and Environmental Sciences, Faculty of Engineering and Science, University of Greenwich, Medway Campus, Central Avenue, Chatham Maritime, UK.
Omar T MansourDepartment of Pharmaceutical, Chemical and Environmental Sciences, Faculty of Engineering and Science, University of Greenwich, Medway Campus, Central Avenue, Chatham Maritime, UK.
Ralf SchweinsInstitut Laue-Langevin, DS/LSS group, 6 rue Jules Horowitz, 38042 Grenoble Cedex 9, France.
Konrad BeckAdvanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Heath Park, Cardiff, UK.
Niklaas J BuurmaPhysical Organic Chemistry Centre, School of Chemistry, Cardiff University, Cardiff, UK.
Christopher E DempseySchool of Biochemistry, Biomedical Sciences Building, University Walk, Clifton, BS8 1TD, UK.
Chris J WrightCentre for NanoHealth, Systems and Process Engineering Centre, College of Engineering, Swansea University, Swansea, UK.
Philip D RyeAlgiPharma AS, Sandvika, Norway.
Katja E HillAdvanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Heath Park, Cardiff, UK.
David W ThomasAdvanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Heath Park, Cardiff, UK.
Elaine L FergusonAdvanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Heath Park, Cardiff, UK.
Cardiff University · GBUniversity of Greenwich · GBAlgiPharma (Norway) · NOClifton Hospital · GBInstitut Laue-Langevin · FRSwansea University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Concerns about acquisition of antibiotic resistance have led to increasing demand for new antimicrobial therapies. OligoG CF-5/20 is an alginate oligosaccharide previously shown to have antimicrobial and antibiotic potentiating activity. We investigated the structural modification of the bacterial cell wall by OligoG CF-5/20 and its effect on membrane permeability. Binding of OligoG CF-5/20 to the bacterial cell surface was demonstrated in Gram-negative bacteria. Permeability assays revealed that OligoG CF-5/20 had virtually no membrane-perturbing effects. Lipopolysaccharide (LPS) surface charge and aggregation were unaltered in the presence of OligoG CF-5/20. Small angle neutron scattering and circular dichroism spectroscopy showed no substantial change to the structure of LPS in the presence of OligoG CF-5/20, however, isothermal titration calorimetry demonstrated a weak calcium-mediated interaction. Metabolomic analysis confirmed no change in cellular metabolic response to a range of osmolytes when treated with OligoG CF-5/20. This data shows that, although weak interactions occur between LPS and OligoG CF-5/20 in the presence of calcium, the antimicrobial effects of OligoG CF-5/20 are not related to the induction of structural alterations in the LPS or cell permeability. These results suggest a novel mechanism of action that may avoid the common route in acquisition of resistance via LPS structural modification.

Indexed as

AlginatesAnti-Infective AgentsCations, DivalentCell MembraneCell Membrane PermeabilityCell WallGlucuronic AcidHexuronic AcidsLipopolysaccharidesMicrobial Sensitivity TestsPseudomonas aeruginosaStreptococcus mutansAlginatesAnti-Infective AgentsCations, DivalentGlucuronic AcidHexuronic AcidsLipopolysaccharides

Identifiers

PMID28361894
PMCPMC5374485
OpenAlexW2603884125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.